Ekedi Ange Veroniqe Ngo Bilong, Rozhkov Andrey N, Shchekochikhin Dmitry Yu, Novikova Nina A, Kopylov Philippe Yu, Bestavashvili Afina A, Ivanova Tatiana V, Zhelankin Andrey V, Generozov Eduard V, Konanov Dmitry N, Akselrod Anna S
Department of Cardiology, Functional and Ultrasound Diagnostics, N.V. Sklifosovsky Institute of Clinical Medicine, I. M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
World-Class Research Center "Digital Biodesign and Personalized Healthcare", I. M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
J Pers Med. 2023 Jul 20;13(7):1161. doi: 10.3390/jpm13071161.
Circulating serum miRNA are increasingly used as biomarkers and potential treatment targets in several clinical scenarios, including cardiovascular diseases. However, the current data on circulating miRNA in thoracic aorta aneurism (TAA) patients are inconclusive. The aim of the present study is to compare the levels of several circulating miRNA in patients with degenerative TAA, coronary artery disease (CAD), and controls for special profile identification. We have identified several candidates for the role of new biomarkers: miR-143-3p, miR-181-5p, miR-126-3p, miR-126-5p, miR-145-5p, miR-150-5p, and miR-195-5p.
Serum samples of 100 patients were analyzed, including 388 TAA patients scheduled for elective surgery, 67 patients with stable CAD and 17 controls, were used for miRNA isolation and identification.
More specific for TAA with very high predictive ability in ROC analysis was an increase in the levels of miR-21-5p, miR-29b-5p, miR-126-5p/-3p, miR-181b-5p, and miR-92a-3p, with the latter microRNA being investigated as a novel potential marker of TAA for the first time.
TAA and CAD patients demonstrated a significant increase in the levels of circulating miR-126-5p/-3p, miR-181b-5p, and miR-29b-3p. More specific for TAA with very high predictive ability in ROC analysis was an increase in the levels of miR-21-5p, -29b-5p, -126-5p/-3p, 181b-5p, and -92a-3p, with the latter microRNA being investigated as a potential marker of TAA for the first time.
循环血清微小RNA(miRNA)在包括心血管疾病在内的多种临床情况下越来越多地被用作生物标志物和潜在的治疗靶点。然而,目前关于胸主动脉瘤(TAA)患者循环miRNA的数据尚无定论。本研究的目的是比较退行性TAA患者、冠状动脉疾病(CAD)患者和对照组中几种循环miRNA的水平,以进行特殊特征识别。我们已经确定了几种可能作为新生物标志物的候选物:miR-143-3p、miR-181-5p、miR-126-3p;miR-126-5p、miR-145-5p、miR-150-5p和miR-195-5p。
分析了100例患者的血清样本,其中包括388例计划进行择期手术的TAA患者、67例稳定型CAD患者和17例对照组,用于miRNA的分离和鉴定。
在ROC分析中,对TAA具有非常高预测能力且更具特异性的是miR-21-5p、miR-29b-5p、miR-126-5p/-3p、miR-181b-5p和miR-92a-3p水平升高,后者是首次作为TAA的新型潜在标志物进行研究。
TAA和CAD患者循环miR-126-5p/-3p、miR-181b-5p和miR-29b-3p水平显著升高。在ROC分析中,对TAA具有非常高预测能力且更具特异性的是miR-21-5p、-29b-5p、-126-5p/-3p、181b-5p和-92a-3p水平升高,后者是首次作为TAA的潜在标志物进行研究。